Stifel Financial’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Sell |
-20,235
| Closed | -$170K | – | 3782 |
|
|
2026
Q2 | $170K | Buy |
20,235
+85
| +0.4% | +$711 | ﹤0.01% | 3547 |
|
|
2026
Q1 | $167K | Buy |
20,150
+566
| +3% | +$5.86K | ﹤0.01% | 3477 |
|
|
2025
Q4 | $242K | Sell |
19,584
-610
| -3% | -$6.54K | ﹤0.01% | 3282 |
|
|
2025
Q3 | $178K | Buy |
+20,194
| New | +$157K | ﹤0.01% | 3372 |
|
|
2024
Q4 | – | Sell |
-11,460
| Closed | -$95.7K | – | 3409 |
|
|
2024
Q3 | $95.7K | Buy |
+11,460
| New | +$104K | ﹤0.01% | 3245 |
|
|
2022
Q1 | – | Sell |
-10,538
| Closed | -$458K | – | 3396 |
|
|
2021
Q4 | $458K | Buy |
10,538
+301
| +3% | +$13.6K | ﹤0.01% | 2636 |
|
|
2021
Q3 | $512K | Buy |
10,237
+6,127
| +149% | +$371K | ﹤0.01% | 2561 |
|
|
2021
Q2 | $258K | Sell |
4,110
-2,124
| -34% | -$136K | ﹤0.01% | 2994 |
|
|
2021
Q1 | $578K | Buy |
6,234
+888
| +17% | +$90.9K | ﹤0.01% | 2386 |
|
|
2020
Q4 | $479K | Sell |
5,346
-4,170
| -44% | -$383K | ﹤0.01% | 2343 |
|
|
2020
Q3 | $984K | Sell |
9,516
-5,230
| -35% | -$564K | ﹤0.01% | 1645 |
|
|
2020
Q2 | $1.17M | Sell |
14,746
-2,575
| -15% | -$192K | ﹤0.01% | 1451 |
|
|
2020
Q1 | $1M | Buy |
17,321
+4,378
| +34% | +$252K | ﹤0.01% | 1432 |
|
|
2019
Q4 | $696K | Sell |
12,943
-2,699
| -17% | -$146K | ﹤0.01% | 2059 |
|
|
2019
Q3 | $817K | Buy |
15,642
+1,404
| +10% | +$65.4K | ﹤0.01% | 1877 |
|
|
2019
Q2 | $690K | Sell |
14,238
-2,595
| -15% | -$124K | ﹤0.01% | 2025 |
|
|
2019
Q1 | $853K | Sell |
16,833
-2,350
| -12% | -$139K | ﹤0.01% | 1752 |
|
|
2018
Q4 | $1.14M | Buy |
19,183
+3,332
| +21% | +$215K | ﹤0.01% | 1451 |
|
|
2018
Q3 | $1.04M | Sell |
15,851
-668
| -4% | -$39K | ﹤0.01% | 1643 |
|
|
2018
Q2 | $831K | Sell |
16,519
-2,395
| -13% | -$125K | ﹤0.01% | 1747 |
|
|
2018
Q1 | $995K | Buy |
18,914
+4,105
| +28% | +$205K | ﹤0.01% | 1566 |
|
|
2017
Q4 | $689K | Buy |
14,809
+1,237
| +9% | +$52.1K | ﹤0.01% | 1738 |
|
|
2017
Q3 | $548K | Hold |
13,572
| – | – | ﹤0.01% | 1828 |
|
|
2017
Q2 | $461K | Buy |
13,572
+513
| +4% | +$15.8K | ﹤0.01% | 1909 |
|
|
2017
Q1 | $379K | Buy |
13,059
+4,401
| +51% | +$134K | ﹤0.01% | 1970 |
|
|
2016
Q4 | $284K | Buy |
+8,658
| New | +$260K | ﹤0.01% | 2068 |
|
|
2016
Q1 | – | Sell |
-6,189
| Closed | -$248K | – | 2272 |
|
|
2015
Q4 | $248K | Buy |
+6,189
| New | +$216K | ﹤0.01% | 2013 |
|
Other funds holding EBS
PGCM
Stifel Financial's EBS Position: Q3 2026 in Review
Stifel Financial sold out of Emergent Biosolutions (EBS) in Q3 2026, closing a stake of 20,235 shares — an estimated $170K sold.
Stifel Financial first reported a position in EBS in Q4 2015 and held it in 27 quarters. The position peaked at $1.17M in Q2 2020. 103 funds tracked by Wall St. Rank hold EBS as of Q3 2026.
- Stifel Financial reported no remaining Emergent Biosolutions position as of Q3 2026 after selling out during the quarter.
- Stifel Financial sold 20,235 Emergent Biosolutions shares in Q3 2026, an estimated $170K.
- Stifel Financial first reported a position in Emergent Biosolutions in Q4 2015 and held it in 27 quarters.
- Stifel Financial's Emergent Biosolutions position peaked at $1.17M in Q2 2020.
- 103 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2026.
Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.